Leadership Overview
ICON has 4 executives leading key functions including corporate strategy, clinical operations, human resources, and biotechnology development.
Focused on accelerating drug and device development, ICON delivers comprehensive commercialization services to global pharmaceutical, biotechnology, and public health organizations while maintaining a commitment to clinical excellence.
Focused on accelerating drug and device development, ICON delivers comprehensive commercialization services to global pharmaceutical, biotechnology, and public health organizations while maintaining a commitment to clinical excellence.
Leadership Roles at ICON
Thomas Marsland - President
Thomas Marsland, the President at ICON, directs high-level corporate strategy and oversees the execution of complex drug development programs. Marsland manages the integration of clinical research services across global markets, ensuring that pharmaceutical and biotechnology clients receive efficient, compliant, and scalable solutions. By aligning operational resources with long-term growth objectives, the President drives the expansion of service capabilities within the medical device sector. Thomas Marsland monitors performance metrics across international regions to maintain competitive advantages in the research landscape. This leadership role involves constant collaboration with the board to refine service delivery models and optimize resource allocation. Through rigorous oversight of project lifecycles, Marsland ensures that ICON meets the evolving demands of public health organizations. The President maintains a focus on operational excellence, fostering an environment where innovation supports the rapid advancement of life-saving therapies for patients worldwide.
Deepali Suri - President, ICON Biotech
Deepali Suri, the President, ICON Biotech at ICON, directs the specialized division focused on biotechnology research and development services. Suri oversees the strategic delivery of clinical development solutions tailored specifically to the unique needs of biotech firms. By managing the lifecycle of drug development programs, the President, ICON Biotech ensures that clients navigate regulatory and commercialization hurdles with precision. Deepali Suri drives the expansion of biotech-specific service offerings, focusing on innovation in clinical trial design and data management. This leadership role involves coordinating with global teams to provide seamless support for complex therapeutic pipelines. Through the application of advanced research methodologies, Suri enhances the value proposition for biotechnology partners, ensuring that ICON remains a leader in the sector. The President, ICON Biotech maintains a focus on operational agility, allowing the organization to respond rapidly to shifts in the biotechnology landscape while supporting the broader corporate mission of advancing global health.
Edward Wright - President
Edward Wright, the President at ICON, directs the commercialization and business development initiatives that support the company's global service portfolio. Wright oversees the strategic partnerships with pharmaceutical and medical device organizations, ensuring that service delivery aligns with client-specific development goals. By focusing on market expansion and the optimization of commercialization pathways, the President drives revenue growth and strengthens the company's position in the research services industry. Edward Wright manages the integration of new service lines, ensuring that ICON provides comprehensive support from early-stage development through to market launch. This leadership role involves analyzing market trends to anticipate the needs of public health organizations and biotechnology firms. Through the implementation of robust business strategies, Wright ensures that the organization maintains high standards of quality and efficiency. The President fosters a culture of accountability, ensuring that all commercial operations contribute directly to the successful delivery of clinical and commercial outcomes.
Marian Colon-Nieves - Manager, Clinical Operations & Chief People Officer
Marian Colon-Nieves, the Manager, Clinical Operations & Chief People Officer at ICON, architects the internal framework for clinical trial execution while simultaneously directing human capital strategies. Colon-Nieves oversees the recruitment, development, and retention of specialized talent necessary for complex drug development projects. By aligning workforce capabilities with clinical operational requirements, the Manager, Clinical Operations & Chief People Officer ensures that teams possess the technical expertise to manage global medical device and pharmaceutical studies. Marian Colon-Nieves implements organizational culture initiatives that promote efficiency and cross-functional collaboration across diverse geographic regions. This dual-focus role requires balancing the immediate demands of clinical trial timelines with the long-term necessity of building a resilient, high-performing workforce. Through strategic talent management and operational oversight, Colon-Nieves supports the company mission of delivering superior research services to public health organizations and biotechnology partners, ultimately driving sustainable growth and operational stability.
Explore Leadership Teams in Business Services
Founded in 1977, Scientific Systems and Applications, Inc. is a science, engineering and information analytics company. SSAI is headquartered out of Lanham, Maryland.
Company Leadership
KC
PB
SS
GHG Corporation is a certified Service-Disabled Veteran Owned Small Business that specializes in engineering and IT services. They offer a wide range of services including safety and mission assurance, hardware development, analysis, testing, evaluation, and space operations. Their clients include both government and commercial sectors, reflecting their commitment to delivering high-quality solutions. GHG Corporation prides itself on its diversity, technical achievements, and dedication to customer satisfaction.
Company Leadership LA
DB
FB
Alpine Intel is dedicated to innovation across a broad range of property insurance intelligence helping our customers reach peak performance throughout the policy life cycle. Through our operating brands, HVACi, StrikeCheck, National Fire Experts, Donan Engineering, and the Component Testing Laboratory, we are respected as the industry leader for our scale and our track record of conducting expert, specialized, and accurate investigations. Headquartered in Charlotte, North Carolina, our team of experienced professionals provides high-quality solutions nationwide. Our commitment to delivering actionable intelligence is the essence of Alpine Intel.
Company Leadership DS

CO
RN
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic.
Company Leadership HH


XL